JAK Inhibitor News and Research

RSS

Engineered CAR T cells show promise against myeloproliferative neoplasms

A new form of CAR T cell therapy has been designed to find and destroy the cancer-driving stem cells responsible for a group of blood cancers known as myeloproliferative neoplasms (MPNs), while leaving healthy blood cells unharmed, in new research led by UCL and University of Oxford researchers.

1 Jul 2026

Study reveals new immune mechanism behind mevalonate kinase deficiency

Researchers at the Garvan Institute of Medical Research have uncovered a critical mechanism driving inflammation in mevalonate kinase deficiency (MKD), a rare but devastating autoinflammatory disorder.

30 Apr 2026

Updated EULAR recommendations guide treatment decisions for rheumatoid arthritis

First published in 2010, the EULAR recommendations for the management of RA, the most frequent inflammatory rheumatic disease, have been relied upon by healthcare professionals and organisations worldwide to offer an up-to-date and robust analysis of the effectiveness and practical use of available DMARDs – from conventional agents such as methotrexate to biologics and Janus kinase (JAK) inhibitors.

13 Mar 2026

PTPN2 gene protects the gut from harmful bacteria driving inflammatory bowel disease

Two recent studies from the University of California, Riverside, published in the same issue of Gut Microbes highlight the role of a gene called PTPN2 in protecting the gut from harmful bacteria linked to inflammatory bowel disease (IBD).

24 Jan 2026

Oral drug baricitinib shows promise in slowing early type 1 diabetes progression

In 2023, the groundbreaking Australian BANDIT (Baricitinib in New Onset Type 1 Diabetes) trial [1] reported that a daily pill of baricitinib, commonly prescribed for rheumatoid arthritis and alopecia, could safely preserve the body's own insulin production and slow the progression of type 1 diabetes (T1D) in people recently diagnosed with the condition.

19 Sep 2025

Arthritis drug shows promise in halting seizures in mice with epilepsy

A drug typically prescribed for arthritis halts brain-damaging seizures in mice that have a condition like epilepsy, according to researchers at the University of Wisconsin–Madison.

25 Mar 2025

Tofacitinib reduces SARS-CoV-2 infection risk in patients with PTPN2 deficiency

Researchers report the ability of tofacitinib to reduce infection risk with SARS-CoV-2 in individuals who are deficient in PTPN2.

17 Jan 2025

Genetic risk factor linked to increased susceptibility to SARS-CoV-2 infection

Researchers have identified a novel genetic risk factor for SARS-CoV-2 infection, providing new insights into the virus' ability to invade human cells. SARS-CoV-2 is the virus that spreads COVID-19.

15 Jan 2025

Researchers uncover the potential of JAK inhibitors to treat life-threatening skin disease

Researchers identified Janus kinase inhibitors as a promising treatment for the severe drug-induced skin condition toxic epidermal necrolysis, by analyzing patient biopsies with deep visual proteomics.

17 Oct 2024

JAK1 inhibition and Anti-PD1 therapy enhance outcomes in advanced lung cancer

Adding an anti-inflammatory drug to anti-PD1 checkpoint inhibitor immunotherapy has shown great promise as a new strategy against advanced lung cancer, based on results from a small clinical trial led by investigators at the Abramson Family Cancer Center at the University of Pennsylvania Perelman School of Medicine.

21 Jun 2024

Combination therapy shows great promise as a new strategy against advanced lung cancer

21 Jun 2024

JAK inhibitor ruxolitinib enhances immunotherapy in Hodgkin lymphoma patients

Checkpoint inhibitor therapies can be thought of as the molecular "brake release" for the immune system.

20 Jun 2024

Unraveling nuanced roles of JAK inhibitors in inflammation

Researchers at the Icahn School of Medicine at Mount Sinai have gained a deeper understanding of the nuanced roles of JAK inhibitors, or modulators, in inflammation across various cell types and tissues.

21 Dec 2023

Two new practice parameters offer recommendations for treating anaphylaxis and atopic dermatitis

Two new practice parameters from the Joint Task Force for Practice Parameters (JTFPP) offer evidence-based recommendations for the diagnosis and management of anaphylaxis and atopic dermatitis (AD) in pediatric and adult patients.

18 Dec 2023

New drug combination doubles effectiveness in shrinking enlarged spleens in myelofibrosis patients

Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens – a major indicator of clinical improvement – compared with standard-of-care ruxolitinib monotherapy for adult patients with intermediate or high-risk myelofibrosis, a rare bone marrow cancer, according to results of the Phase III TRANSFORM-1 trial reported by researchers from The University of Texas MD Anderson Cancer Center.

11 Dec 2023

JAK inhibitors offer effective and convenient treatment option for arthritis patients

According to a new paper in Rheumatology, published by Oxford University Press, JAK inhibitors, which doctors have used to treat patients with arthritis despite concerns about the effectiveness of such drugs, actually do work quite well.

1 Nov 2023

Lack of direct comparisons prevents assessment of upadacitinib's benefit in Crohn's disease

Like several immunosuppressive biologics, the JAK inhibitor upadacitinib is also approved for the treatment of Crohn's disease. Commissioned by the Federal Joint Committee (G-BA), the Institute for Quality and Efficiency in Health Care (IQWiG) has now investigated in an early benefit assessment whether the drug offers an added benefit versus the appropriate comparator therapy to patients with moderate to severe active Crohn's disease who have had an inadequate response, lost response or are intolerant to conventional therapy or a biologic agent.

25 Oct 2023

Differences in immune responses to IL-6 inhibition therapy between male and female COVID-19 patients

Researchers investigated whether anti‑interleukin 6 monoclonal antibodies were related to heterogenous treatment effects between male and female COVID-19 patients.

24 Aug 2023

Study reveals immune dysregulation in Down syndrome and potential therapeutic strategy

People with Down syndrome, the condition caused by an extra copy of chromosome 21, or trisomy 21, display chronic dysregulation of their immune system, which can contribute to high rates of autoimmune conditions and severe complications from respiratory infections.

17 Jul 2023

Scientists uncover molecular mechanism contributing to defective heart development in Down syndrome

Infants born with Down syndrome, the genetic condition caused by an extra copy of chromosome 21, or trisomy 21, are highly predisposed to congenital heart defects.

21 Jun 2023